Corpus ID: 11928697

Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

@article{Cao2001InterferoninducibleP1,
  title={Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).},
  author={Z. Cao and B. Baguley and L. Ching},
  journal={Cancer research},
  year={2001},
  volume={61 4},
  pages={
          1517-21
        }
}
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a drug synthesized in this laboratory that halts tumor blood flow and induces tumor hemorrhagic necrosis in transplantable murine tumors, is known to induce the synthesis of antiangiogenic cytokines in vitro. We have measured the induction of mRNA for modulators of angiogenesis in vivo and investigated whether DMXAA may also have an additional antiangiogenic action through the production of these cytokines. The genes for IFN-alpha and for interferon… Expand
IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
  • Z. Roberts, L. Ching, S. Vogel
  • Biology, Medicine
  • Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • 2008
TLDR
Results support the conclusion that DMXAA derives its potent anticancer properties in part through elicitation of IFN-beta expression by host-derived elements. Expand
Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites.
TLDR
The results indicate that DMXAA rather than a metabolite is responsible for cytokine induction and suggest that the microenvironment of the tumour may be responsible for the observed selective induction of cytokines in tumour tissue. Expand
NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
TLDR
The antitumour action of DMXAA appears to be independent of the ability of the target tumour cell population to induce NF-kappaB expression, as shown by electrophoretic mobility shift assays (EMSAs). Expand
p38 Mitogen-Activated Protein Kinase Is Required for the Antitumor Activity of the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-acetic Acid
TLDR
In vivo p38 MAPK inhibition attenuated the immediate reduction in tumor blood flow induced by DMXAA treatment by inhibiting actin cytoskeleton reorganization in tumor vascular endothelial cells and blunted the long-lastingDMXAA-induced shutdown of the tumor vasculature by inhibited intratumoral TNF-α production. Expand
Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
TLDR
Activation of tumor-associated macrophages by DMXAA is an efficient way to generate a CD8(+) T-cell-dependent antitumor immune response even in animals with relatively nonimmunogenic tumors. Expand
The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
TLDR
Results indicate DMXAA acts in vitro on HPBL to co-stimulate TNF production by a wide variety of agents, and suggests that IkappaB kinase is the target that mediates this action. Expand
Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) acts through tumor vascular disruption and cytokine production and is the first of its class to enter phase 3 trials. We characterized leukocytes andExpand
Stimulation of TNF-α production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) – a novel immunomodulator with potential application in tumour immunotherapy
TLDR
AdAMP seems to be a therapeutically promising compound with potential application as an adjuvant augmenting the efficacy of cancer vaccine-based therapies or in the local treatment of certain tumours. Expand
Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
TLDR
It is concluded that 5,6-Dimethylxanthenone-4-acetic acid can induce vascular endothelial cell apoptosis in some murine and human tumours and appears to be independent of tumour necrosis factor induction. Expand
Abstract 930: p38 MAPK is required for the antitumor activity of the vascular disrupting agent DMXAA
TLDR
It was found that p38 MAPK was critically involved in DMXAA-induced cytoskeleton reorganization in endothelial cells and TNF-α production in macrophages, both of which were essential for DMXaa-induced vascular disruption. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
TLDR
It is shown here that the extent of DMXAA-induced TNF synthesis is greater in tumors than that in the spleen, liver, or serum, and the use of low molecular weight agents to induce T NF synthesis in situ in the tumor represents a novel approach to TNF-mediated therapy of cancers. Expand
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
TLDR
Results confirm that DMXAA has the novel ability of inducing tumors to synthesize TNF in situ. Expand
Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation.
TLDR
Data suggest that 5,6-MeXAA shares with LPS certain biochemical pathways that lead to gene induction and allow for the additional dissection of the relationship of tyrosine phosphorylation and the expression of specific genes. Expand
Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
TLDR
The results suggest that 5,6-MeXAA would be a more active clinical agent than FAA because TNF-alpha induction appears to be a critical factor in the antitumor effects of this class of compounds. Expand
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.
TLDR
The results demonstrate that the host response to IFN-gamma is not essential for an anti-tumour response and are consistent with the concept that the antitumour activity of DMXAA involves complex immunomodulation, probably with significant redundancy in contributing cytokines. Expand
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10.
TLDR
It is reported that murine IL- 12 profoundly inhibited basic fibroblast growth factor (bFGF)-induced Matrigel neovascularization in vivo, and that this effect of IL-12 was neutralized by systemic administration of antibodies to either murine IFN-gamma or IP-10. Expand
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
TLDR
It is reported that IP-10 is a potent inhibitor of angiogenesis in vivo and the possibility that IP -10 may participate in the regulation ofAngiogenesis during inflammation and tumorigenesis is raised. Expand
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
TLDR
The results suggest a possible new application for thalidomide and pose new questions about the action of 5,6-MeXAA and related compounds. Expand
Mice by Systemic Interferon-Angiogenesis , and Growth of Human Bladder Carcinoma in Inhibition of Basic Fibroblast Growth Factor Expression
The purpose of these studies was to determine whether systemic ad ministration of IFN-a can inhibit the expression of basic fibroblast growth factor (bFGF) in human transitional cell carcinoma,Expand
Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
TLDR
The results demonstrate that the tumor-bearing state induces an abnormal cytokine network under which the production of antitumor cytokines is negatively regulated. Expand
...
1
2
3
4
5
...